A number of unionized employees at MindsEye developer Built a Rocket Boy have taken legal action against the [...] ...

Christopher North, founding keyboardist for prog- and soft-rock standouts Ambrosia, has died. He was 75. Described in Ambrosia’s statement as the “Hammond B3 King” for his work on the instrument, the ...

Christopher North, a founding member of the rock band Ambrosia, has died. He was 75. The band confirmed North’s heartbreaking passing in a Facebook post on Monday. “Fans of Ambrosia, we honor the ...

Christopher North, the founding keyboardist of 1970s rock band Ambrosia, has died. He was 75. The news of his death was confirmed in a Facebook post shared by the official Ambrosia account. “Fans of ...

This is read by an automated voice. Please report any issues or inconsistencies here. Christopher North, who played keyboards as a founding member of the soft-rock group Ambrosia, died Monday in a ...

Add Yahoo as a preferred source to see more of our stories on Google. Keyboard player Christopher North of Ambrosia performs onstage on May 23, 2015 in Bakersfield, California. (Photo by Scott ...

Ambrosia keyboardist Christopher North has died at 75. His progressive rock band, known for the 1978 hit “How Much I Feel” and 1980’s “Biggest Part of Me,” announced “Northwind’s” death on Monday ...

Soft Rains Games has announced that it will be releasing Ambrosia Sky Act Two as a free update for all players that own Ambrosia Sky Act One, but the price of the game will increase after Act Two is ...

Ambrosia keyboardist Christopher North has died at 75. Related Articles Ex-first lady Jill Biden bid $35,000 for role on ‘Heated Rivalry’ Bob Odenkirk relishes return to small-town roots in ‘Normal’ ...

Christopher North - the founding keyboardist of 1970s rock band Ambrosia - has died at the age of 75 following a battle with throat cancer. The musician’s death was confirmed by the band in a ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million ...